Dechra Pharmaceuticals PLC (OTCMKTS:DCHPF) Short Interest Update

Dechra Pharmaceuticals PLC (OTCMKTS:DCHPFGet Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 58,800 shares, a growth of 17.6% from the August 15th total of 50,000 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Dechra Pharmaceuticals Stock Performance

Shares of Dechra Pharmaceuticals stock opened at $47.32 on Tuesday. Dechra Pharmaceuticals has a 1 year low of $27.90 and a 1 year high of $47.40. The firm’s 50-day moving average is $46.61 and its 200 day moving average is $39.27.

Analyst Ratings Changes

Separately, Stifel Nicolaus cut Dechra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 27th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4,000.00.

Check Out Our Latest Stock Analysis on Dechra Pharmaceuticals

Dechra Pharmaceuticals Company Profile

(Get Free Report)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Featured Stories

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.